{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:07:56Z","timestamp":1779167276857,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010882","name":"Tianjin Municipal Education Commission","doi-asserted-by":"publisher","award":["2023YXZX08"],"award-info":[{"award-number":["2023YXZX08"]}],"id":[{"id":"10.13039\/501100010882","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.transproceed.2026.02.019","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:38:52Z","timestamp":1772109532000},"page":"526-531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peptide Receptor Radionuclide Therapy for Recurrent Neuroendocrine Tumor Liver Metastases After Liver transplantation: A Case Series"],"prefix":"10.1016","volume":"58","author":[{"given":"Chiyi","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4967-2054","authenticated-orcid":false,"given":"Qiming","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingjun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honghai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jisan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wentao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.transproceed.2026.02.019_bib0001","article-title":"Primary hepatic neuroendocrine tumor: a case report and literature review","volume":"14","author":"Elayan","year":"2022","journal-title":"Cureus."},{"key":"10.1016\/j.transproceed.2026.02.019_bib0002","doi-asserted-by":"crossref","first-page":"1001163","DOI":"10.3389\/fonc.2022.1001163","article-title":"Liver transplantation in gastroenteropancreatic neuroendocrine tumors","volume":"12","author":"Fernandes","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.transproceed.2026.02.019_bib0003","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000494760","article-title":"Targeted alpha particle therapy for neuroendocrine tumours: the next generation of peptide receptor radionuclide therapy","volume":"108","author":"Navalkissoor","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"5","key":"10.1016\/j.transproceed.2026.02.019_bib0004","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1053\/j.ajkd.2017.05.024","article-title":"Peptide receptor radionuclide therapy-induced gitelman-like syndrome","volume":"70","author":"Negro","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1016\/j.transproceed.2026.02.019_bib0005","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high\u2011dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.transproceed.2026.02.019_bib0006","doi-asserted-by":"crossref","first-page":"491","DOI":"10.7150\/thno.51215","article-title":"Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response","volume":"11","author":"Feijtel","year":"2021","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.transproceed.2026.02.019_bib0007","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1097\/RLU.0000000000003618","article-title":"Discordant uptake between diagnostic 68Ga-HA-DOTATATE PET\/CT and posttherapy 177Lu-HA-DOTATATE SPECT\/CT in patients with neuroendocrine tumors","volume":"46","author":"Huizing","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1016\/j.transproceed.2026.02.019_bib0008","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/oncolo\/oyab072","article-title":"Evaluation of liver and renal toxicity in peptide receptor radionuclide therapy for somatostatin receptor expressing tumors: a 2-year follow-up","volume":"27","author":"Duan","year":"2022","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.transproceed.2026.02.019_bib0009","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s13139-020-00679-y","article-title":"Peptide receptor radionuclide therapy of pulmonary neuroendocrine neoplasms: a single-centre experience","volume":"55","author":"Minutoli","year":"2021","journal-title":"Nucl Med Mol Imaging"},{"issue":"7","key":"10.1016\/j.transproceed.2026.02.019_bib0010","first-page":"578","article-title":"Liver transplant for patients with neuroendocrine tumor: a report of 2 exceptional cases and literature review","volume":"21","author":"Moradi","year":"2023","journal-title":"Exp Clin Transplant"},{"issue":"2","key":"10.1016\/j.transproceed.2026.02.019_bib0011","doi-asserted-by":"crossref","first-page":"100595","DOI":"10.1016\/j.trre.2021.100595","article-title":"Neuroendocrine liver metastases: the role of liver transplantation","volume":"35","author":"D\u2019Amico","year":"2021","journal-title":"Transplant Rev (Orlando)"},{"issue":"5","key":"10.1016\/j.transproceed.2026.02.019_bib0012","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1158\/1535-7163.MCT-23-0342","article-title":"Enhanced antipediatric sarcoma effect of everolimus with secukinumab by targeting IL17A","volume":"23","author":"Huang","year":"2024","journal-title":"Mol Cancer Ther"},{"issue":"31","key":"10.1016\/j.transproceed.2026.02.019_bib0013","doi-asserted-by":"crossref","first-page":"eadf3566","DOI":"10.1126\/sciadv.adf3566","article-title":"PHF8-GLUL axis in lipid deposition and tumor growth of clear cell renal cell carcinoma","volume":"9","author":"Peng","year":"2023","journal-title":"Sci Adv"},{"issue":"9","key":"10.1016\/j.transproceed.2026.02.019_bib0014","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.2967\/jnumed.123.265484","article-title":"Specific uptake in the bone marrow causes high absorbed red marrow doses during [177Lu]Lu-DOTATATE treatment","volume":"64","author":"Hemmingsson","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.transproceed.2026.02.019_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.156659","article-title":"Validated herbal extracts for alleviating chemotherapy-induced myelosuppression: A systematic review and meta-analysis","volume":"141","author":"Wang","year":"2025","journal-title":"Phytomedicine"},{"issue":"3","key":"10.1016\/j.transproceed.2026.02.019_bib0016","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000657","article-title":"Liver involvement in a large cohort of patients with erythropoietic protoporphyria or X-linked protoporphyria","volume":"9","author":"Levy","year":"2025","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.transproceed.2026.02.019_bib0017","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0000000000004303","article-title":"Nodular regenerative hyperplasia is not a rare condition after liver transplantation: incidence, predictive factors, and impact on survival","volume":"107","author":"Kounis","year":"2023","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.transproceed.2026.02.019_bib0018","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000002626","article-title":"Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM study","volume":"103","author":"Tedesco-Silva","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2026.02.019_bib0019","article-title":"Peptide receptor radionuclide therapy: a new era of radiation nephropathy","author":"Das","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.transproceed.2026.02.019_bib0020","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1007\/s00259-025-07235-w","article-title":"Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours - a single centre experience","volume":"52","author":"Kashyap","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.transproceed.2026.02.019_bib0021","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(20)30027-9","article-title":"Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study","volume":"21","author":"Braat","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.transproceed.2026.02.019_bib0022","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1245\/s10434-020-08787-x","article-title":"The landmark series: neuroendocrine tumor liver metastases","volume":"27","author":"Gangi","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.transproceed.2026.02.019_bib0023","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/MNM.0000000000001284","article-title":"Y90 selective internal radiation therapy and peptide receptor radionuclide therapy for the treatment of metastatic neuroendocrine tumors: combination or not?","volume":"41","author":"Yilmaz","year":"2020","journal-title":"Nucl Med Commun"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134526001004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134526001004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:16:04Z","timestamp":1779164164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134526001004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0041134526001004"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2026.02.019","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptide Receptor Radionuclide Therapy for Recurrent Neuroendocrine Tumor Liver Metastases After Liver transplantation: A Case Series","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2026.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}